This research was presented at the American Association for Cancer Research (AACR) annual meeting on March 31st in Atlanta, Georgia.
David Andrews, MD, Professor of Neurosurgery at the Vickie & Jack Farber Institute for Neuroscience — Jefferson Health and co-founder, Chief Medical Officer and interim Chief Executive Officer of Imvax, said in a press release, “We look forward to initiating a phase II trial later this year to confirm these phase 1b results.”
“As a consequence of the combined effects of the IGF-1R antisense and irradiation, our evidence shows that the chambered tumor cells release antigens, which together with the immunomodulatory AS-ODN, diffuse out of the chamber into the patient’s body and activate the immune system against brain tumor cells,” says immunologist D. Craig Hooper, PhD, a Professor of Cancer Biology at the Sidney Kimmel Cancer Center – Jefferson Health and a co-founder and Chief Scientific Officer of Imvax.
The phase 1b clinical trial builds on earlier work showing that standard-of-care treatment for glioblastoma damages the immune system and suggesting that the vaccine would be more effective in patients whose immune systems had not been compromised by prior therapy.
IGV-001 has been granted orphan drug designation for the treatment of malignant gliomas by the US Food and Drug Administration (affects fewer than 200,000 people in the US) and the European Medicines Agency (affects fewer than 5 in 10,000 in the EU).
Glioblastoma is the most aggressive type of primary brain cancer, one with a prognosis of 11-15 months with standard treatment.
Glioblastomas (also called GBM) are malignant Grade IV tumors, where a large portion of tumor cells are reproducing and dividing at any given time. They are nourished by an ample and abnormal tumor vessel blood supply.